Navigation Links
Viroblock SA Reports Positive Results of Preclinical Studies in Antiviral Nasal Spray

GENEVA, Switzerland, March 31 /PRNewswire/ -- Viroblock SA has announced today that the first generation of VCCD Tech antiviral nasal spray formulation is active against human influenza. Viroblock's patented Cholesterol Catalytic Depletion Technology (VCCD Tech) inactivates enveloped viruses during the extra-cellular phase, by altering and destabilizing cholesterol-rich viral envelopes.

The two pre-clinical studies exposed ferrets to Influenza A Wisconsin/67/2005 and influenza A Panama/2007/99 strains, and were conducted by Retroscreen Virology Ltd, a recognized leader in the research and testing of antiviral compounds and vaccines. Both the direct inoculation and the natural transmission protocols have confirmed the effectiveness and the value of the antiviral nasal spray.

These in-vivo campaigns confirm all in laboratory in-vitro studies to date and demonstrate that VCCD Tech represents a breakthrough for inactivating a number of enveloped viruses and their strains.

"Our depletion technology shows no toxicity at the dosage we tested thus far and allegedly limits the development of any viral resistance, and makes it effective on all families of enveloped viruses, such as human and avian influenzas, SARS, AIDS, Ebola and smallpox viruses."

"This is an exciting development period for Viroblock and the most recent pre-clinical performance is a testament to our innovative and cutting-edge technology, the quality of our team, board of directors and investors."

"We, at Viroblock, leverage all our technological assets for rapidly developing the next generation of antiviral nasal sprays; I am also confident that our technology will become an important element of pandemic influenza preparedness efforts".

"Our ability to deliver tailored antiviral formulations, which can exist as colloidal suspensions, gels, creams, and aerosol sprays, opens promising business opportunities and a bright future for Viroblock.", comments CEO Thierry Pelet.

About Viroblock SA

Viroblock SA is a Swiss start-up founded in 2005, which has become a pioneer and world leader in the blocking virus transmission technology.

Its patented VCCD technology allegedly inactivates all families and strains of enveloped viruses, like human and avian influenzas, RSV, SARS, AIDS, Ebola and smallpox viruses, and leverages a mechanism of action that limits the development of any viral resistance and toxicity. VCCD Tech products exist as colloidal suspensions, gels, creams, and aerosol sprays, having specific mechanical, physical and chemical properties

The W.A. De Vigier Foundation nominated Viroblock SA as one of the 10 best technology projects of the year 2006, and the Swiss Tech Tour 2007 Selection Committee has rated Viroblock SA as part of the top 50 technology companies in Switzerland.

Viroblock was founded by Dr. Donald F. H. Wallach who was a worldwide expert in artificial and bio-membranes, and non-phospholipid vesicles.

    Additional information is available on the company's website at


    Thierry Pelet
    Chief Executive Officer
    Viroblock SA
    Phone: +41-22-884-83-44

SOURCE Viroblock SA
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments
2. IDM Pharma Reports 2008 Financial Results
3. BioSpecifics Technologies Corp. Reports Fourth Quarter and Full Year 2008 Financial Results
4. Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session
5. TorreyPines Therapeutics Reports Fourth Quarter and Full Year 2008 Results
6. Catalyst Pharmaceutical Partners Reports Fourth Quarter and Year-End 2008 Financial Results
7. Cornerstone Therapeutics Reports Year Ended December 31, 2008 Financial Results
8. ADVENTRX Pharmaceuticals, Inc. Reports Fourth Quarter and Full Year 2008 Financial Results
9. Cell Therapeutics, Inc. Reports Outcome of Special Meeting of Shareholders
10. China Bio Energy Reports Fourth Quarter and Record 2008 Financial Results
11. Neogen Reports Record Third Quarter
Post Your Comments:
(Date:11/24/2015)... 24, 2015  Tikcro Technologies Ltd. (OTCQB: TIKRF) today announced that its ... at 11:00 a.m. Israel time, at the law ... Allon Street, 36 th Floor, Tel Aviv, Israel ... and Izhak Tamir to the Board of Directors; ... directors; , approval of an amendment to certain terms of options ...
(Date:11/24/2015)... 2015  Twist Bioscience, a company focused on ... Twist Bioscience chief executive officer, will present at ... 1, 2015 at 3:10 p.m. Eastern Time at The Lotte ... --> --> About ... is on Twitter. Sign up to follow our ...
(Date:11/24/2015)... , ... November 24, 2015 , ... InSphero AG, the ... cell culture models, has promoted Melanie Aregger to serve as Chief Operating Officer. ... served on the management team and was promoted to Head of InSphero ...
(Date:11/24/2015)... /CNW Telbec/ - ProMetic Life Sciences Inc. (TSX: PLI) (OTCQX: ... Pierre Laurin , President and Chief Executive Officer of ProMetic, ... Jaffray 27 th Annual Healthcare Conference to be held ... st , at 8.50am (ET) and ProMetic,s ... day. The presentation will be available live via a webcast ...
Breaking Biology Technology:
(Date:11/11/2015)...   MedNet Solutions , an innovative SaaS-based eClinical technology ... pleased to announce that it will be a Sponsor of ... to be held November 17-19 in Hamburg ... of iMedNet , MedNet,s easy-to-use, proven and ... has been able to deliver time and cost savings of ...
(Date:11/4/2015)... , November 4, 2015 ... new market report published by Transparency Market Research "Home Security ... Trends and Forecast 2015 - 2022", the global home security ... 30.3 bn by 2022. The market is estimated to ... period from 2015 to 2022. Rising security needs among ...
(Date:10/29/2015)... 29, 2015  Rubicon Genomics, Inc., today announced ... of its DNA library preparation products, including the ... ThruPLEX Plasma-seq kit. ThruPLEX Plasma-seq has been optimized ... NGS libraries for liquid biopsies--the analysis of cell-free ... applications in cancer and other conditions. Eurofins Scientific ...
Breaking Biology News(10 mins):